-Reuters
BTIG Downgrades Taysha Gene Therapies to Neutral
BTIG analyst Yun Zhong downgrades Taysha Gene Therapies (NASDAQ:TSHA) from Buy to Neutral.
Related Posts
Dentsply Sirona Gets Analyst Upgrade After Positive Mixture Of Preliminary Results, Update
On Wednesday, Dentsply Sirona Inc (NASDAQ:XRAY) announced interim FY22 sales above the high end of the company’s prior outlook range…
iMedia Secures Exclusivity Agreement With Its Two Largest Vendors
iMedia Brands Inc (NASDAQ:IMBI) has signed five-year exclusivity agreements with two of ShopHQ’s largest vendors. The vendors are Invicta Watch Company of…
Europe OKs Biogen’s Vumerity For Multiple Sclerosis
The European Commission has approved Biogen Inc’s (NASDAQ:BIIB) Vumerity (diroximel fumarate) to treat adults with relapsing-remitting multiple sclerosis (MS). Vumerity is…